Adjuvant therapy of chronic gastroduodenitis in children with dysplasia of connective tissue

Authors

  • О. М. Mukvich Institute of Pediatrics, Obstetrics and Gynaecology of NAMS Ukraine, Kyiv,
  • D. S. Yankovskyi Scientific Production Company “OD Prolisok”, Kyiv, Ukraine,
  • V. P. Shirobokov O. O. Bogomolets National Medical University, Kyiv, Ukraine,
  • H. S. Dyment Scientific Production Company “OD Prolisok”, Kyiv, Ukraine,
  • О. V. Lavrenchuk Public Non-Profit Enterprise “Center of Primary Medical and Sanitary Health № 1”, Shevchenko District, Kyiv, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2018.02.125584

Keywords:

children, hypertrophic gastroduodenitis, connective tissue diseases, treatment, probiotics

Abstract

Chronic gastroduodenitis (CGD) hold one of main places among leading diseases of gastro-intestinal tract (GIT) in childhood. A special category is children who have CGD against the background of connective tissue (CT) dysplasia (DCT). CGD in such children is characterized by early appearance, aggressive, gradient course with frequent acute conditions and recurrences with evident symptoms of nonspecific intoxication manifestations. Defect of collagen synthesis leads to pronounced morphological changes of proximal GIT mucous membrane (MM) and decline in its cytoptotecive abilities. Challenges related to the qualitative and quantitative local ecosystem changes can aggravate immune and metabolic local processes and enhance the destruction of proximal GIT mucous membrane. Aforesaid defines the need to include multiprobiotics into the treatment schemes of patient with CGD, associated with congenital fibrogenesis disorders, as adjuvant therapy with complex therapeutic action; they positively influence the CT metabolism, improve reparative processes in MM, normalize immune processes and maintain composition and functions of physiological microbiota.

Purposes – improvement of CGD treatment efficiency in children with DCT through inclusion of the multiprobiotic Symbiter® forte-M into the treatment schemes.

Materials and methods. There were examined 33 children with CGD on the background of DCT and 32 healthy children (control) from 11 to 17 years old. The state of the mucous barrier was estimated by certain mucin constituents (fucose, glycosaminoglycans, sialic acids) assessing, antimicrobial peptides (ß2-defencins), non-specific humoral factors of the local immunity (immunoglobulins, lysozyme) in mucous secretions (saliva, coprofiltrate (CF)) before and after probiotic therapy.

Results. Increased concentrations of ß2-defencins (psaliva = 0.03, pCF = 0.03), sialic acids (P = 0.04) and lysozyme (P = 0.01) and decreased of fucose level (P = 0.03) in mucous secretions under application of multicomponent probiotic preparation were observed.

Conclusions. In children with DCT and CGD development, mucins, forming protective homeostatic barrier between residential microbiota and basic immune intestinal cells, contain in their composition increased quantity of fucose-containing glycoproteins and low amount of sialic acids; this influences microbiota and activity of cytoprotective and reparative processes in MM.

Inclusion of the multiprobiotic Symbiter® forte-M into the standard treatment scheme leads to the normalization of some mucus glycoproteins and non-specific humoral local immunity factors. Due to its complex composition with high probiotic and immunomodulatory properties and natural mineral gel (smectite) inclusion, the multiprobiotic improves cytoprotective and reparative properties of GIT mucous membrane and reduces the likelihood of severe destructive processes in children with CGD and DCT development.

References

Nakaz MOZ Ukrainy «Pro zatverzhennia unifikovanykh protokoliv medychnoi dopomohy ditiam iz zakhvoriuvanniamy orhaniv travlennia» vid 29.01.2013 roku №59 [Order of Ministry of Health ‘Defining unified protocols of medical assistance to children with digestive system diseases’ from January 29, 2013, №59]. Retrieved from http://www.moz.gov.ua. [in Ukrainian].

Kondrashova, V. H., Kolpakov, I. Ye., Vdovenko, V. Yu., Hrytsenko, T. V., Shepeliuk, T. V., Studenikina, O. N., & Stepanova, Ye. I. (2014) Kliniko-anamnestychni osoblyvosti patolohii shlunkovo-kyshkovoho traktu u ditej iz syndromom dysplazii spoluchnoi tkanyny sertsia, yaki narodylysia vid batkiv, oprominenykh u dytiachomu vici v rezultati avarii na CHAES [Clinical and anamnestic features of pathology of gastrointestinal tract in children with syndrome of heart connective tissue dysplasia, born to parents irradiated in childhood due to the Chernobyl accident]. Zdorov'e rebenka, 6, 57–60. [in Ukrainian].

Mukvich, O. M., Lavrenchuk, O. V., Gridina, T. A., & Poluk, T. A. (2015) Osoblyvosti klinichnoho perebihu khronichnoho hastroduodenitu u ditei z dysplazieiu spoluchnoi tkanyny [Clinical picture of chronic gastroduodenitis in children with connective tissue dysplasia]. Perinatolohiya i pediatriya, 1(61), 81–86. [in Ukrainian]. doi: 10.15574/PP.2015.61.81.

Shpagin, V. A (2015) Dejstvie selena na immunitet i antioksidantnuyu zashchitu u detej s khronicheskim gastroduodenitom [The impact of selenium on the immune system and antioxidant defense of children with deep-rooted gastroduodenitis]. MEDICUS, 4(4), 59–61. [in Russian].

Bengmark, S. (2012) Gut microbiota, immune development and function. Pharmacol. Res., 69(1), 87–113. doi: 10.1016/j.phrs.2012.09.002.

Duary, R. K., Bhausaheb, M. A., Batish, V. K., & Grover, S. (2012) Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol. Biol. Rep., 39(4), 4765–4775. doi: 10.1007/s11033-011-1269-1.

Khamagaeva, I. S. (2014) Perspektivy ispol'zovaniya probioticheskikh mikroorganizmov v sovremennoj biotekhnologii [Prospects for the use of probiotic microorganisms in modern biotechnology]. Vestnik VSGUTU, 5(50), 111–116. [in Russian].

Shyrobokov, V. P., Yankovsky, D. S., & Dyment, H. S. (2014) Mikrobiom liudyny ta suchasni metody yoho ozdorovlennia [Human microbiom and modern methods of its sanitation]. Infektsiini khvoroby, 2, 64–69. [in Ukrainian].

Abbakumova, L. N. (2006) Displaziya soiedinitiel'noj tkani [Connective tissue dysplasia]. Saint Petersburg. [in Russian].

Makarova, S. G (2013) Prebiotiki kak funkcional'nyj component pitaniya rebenka [Prebiotics as a «Functional» Component of Child Nutrition]. Voprosy sovremennoj pediatrii, 12(5), 8–17. [in Russian].

Downloads

How to Cite

1.
Mukvich ОМ, Yankovskyi DS, Shirobokov VP, Dyment HS, Lavrenchuk ОV. Adjuvant therapy of chronic gastroduodenitis in children with dysplasia of connective tissue. Zaporozhye Medical Journal [Internet]. 2018Mar.7 [cited 2024Nov.13];(2). Available from: http://zmj.zsmu.edu.ua/article/view/125584

Issue

No. 2 (2018)

Section

Corporate information

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)